Frontiers in Immunology SJR and Scopus Metrics: What They Actually Mean

The useful summary is that Frontiers in Immunology sells breadth, accessibility, and section-specific routing more than editorial scarcity. That is why the metrics are good but not elite, and why the journal works well for some manuscripts and poorly for others.

The 2024 picture is a mild strengthening year versus 2023, but still below the early-2020s peak.

• SJR moved up from 1.868 in 2023 to 1.941 in 2024

• impact score moved up from 5.62 to 5.69

• global rank moved slightly from 1521 to 1527

That tells you the journal stabilized a bit after softening from the 2020-2021 high. It remains broadly visible, but no longer carries the stronger prestige-weighted concentration it had several years ago.

The trend shows a journal that grew into a strong field presence, peaked in prestige weighting around the mid-2010s to early-2020s, and then normalized into a still-solid but less concentrated position.

For authors, the trend usually means:

• the journal still gives papers real discoverability in immunology

• the broad OA model remains a meaningful asset

• the journal is not operating as a top-scarcity flagship

• section fit and paper maturity matter more than quartile reassurance

That last point is what authors most often miss. The metric profile can be good while the fit is still wrong.

Frontiers' own about page describes the journal as a multidisciplinary venue spanning basic, translational, and clinical immunology, with submissions routed directly into one of many specialty sections. The same page says manuscripts without a clear immunological contribution, or computational analyses without appropriate validation, are not suitable.

In practice, that means editors are usually screening for:

• a clear specialty-section fit

• an obvious immunology contribution

• enough validation for broad readership confidence

• a manuscript mature enough for section-led external review

That is a real filter. It is just a different filter from top-scarcity journals.

For Frontiers in Immunology metric questions, three mistakes recur.

The broad-scope mistake. Authors often assume broad scope means vague fit is fine. At this journal, section fit still matters.

The validation mistake. Another common miss is computational or descriptive immunology work without enough validation for a broad section audience.

The prestige-substitution mistake. We also see teams use the Q1 label as a substitute for deciding whether they really want the Frontiers editorial model. The metrics confirm visibility. They do not settle the strategic question.

That is the practical meaning of the current profile. Frontiers in Immunology is a serious option, but a specific one.

For authors, the current profile says:

• publication here still carries meaningful discoverability

• the archive is big enough that papers can travel across immunology subfields

• the journal's value is breadth and openness more than scarcity

• the main decision is whether the section-led model fits the paper and the team

The h-index of 259 matters because it reflects a substantial archive of papers that continue to be found and reused in immunology. That is a real signal, even if it is not elite scarcity.

Before you let the Q1 label or CiteScore settle the decision, run a short benchmark on the manuscript.

That benchmark is more useful than staring at SJR. If the paper fails the section-fit or validation test, the current metrics do not rescue the submission.

The better question is whether the manuscript is truly a Frontiers in Immunology paper in its current form.

That is why the next useful reads are:

• Frontiers in Immunology JIF

• Frontiers in Immunology acceptance rate

• Frontiers in Immunology submission guide

• Frontiers in Immunology journal profile

If the section fit is clear and the paper benefits from broad OA immunology exposure, the current metrics support the choice. If the real need is tighter audience targeting or stronger scarcity signaling, the profile is warning you not to overread the quartile. A Frontiers in Immunology submission readiness check is a direct way to pressure-test that before submission.

Frontiers in Immunology still has a strong enough Scopus profile to be taken seriously as a broad immunology venue. The 2024 numbers confirm real visibility and legitimacy, not elite scarcity.

For authors, the metric question is straightforward. The live question is whether the journal's section-led broad OA model is actually the right fit.

1. Frontiers in Immunology JIF, Manusights.